Stay informed about EMBL news by subscribing to press releases.
For more information please contact the Press Officer:
Meyerhofstraße 1, Heidelberg, 69117, Germany
Tel: +49 6221 387-8443
Heidelberg, 21 December 2017 Mapping molecules on people, fields and ATM machines Every day, every inch of skin on your body comes into contact with thousands of molecules – from skin cream, sweat, even from the microbes that call your skin home. Now scientists can create interactive 3D maps that show where each molecule lingers on our bodies, but also on other objects, thanks to a new method that researchers at EMBL and University of California San Diego have made available in Nature Protocols.
Heidelberg, 31 August 2017 German state and federal governments agree on funding for a high-resolution microscopy centre in Heidelberg The German state and federal governments have agreed on funding for a high-resolution microscopy centre at EMBL in Heidelberg. The letter of intent was signed today during an official ceremony at EMBL's Heidelberg campus by representatives of the German government together with industry and foundation partners. The new centre for light and electron microscopy will be a unique service facility for the life sciences and unite cutting-edge equipment, experts and data analysis. It will be open to visiting scientists from all over the world as well as industry partners.
Heidelberg, 28 June 2017 EMBL Council selects next Director General At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organisation's fifth Director General. Heard's mandate is scheduled to begin 1 January 2019. She is currently Director of the Genetics and Developmental Biology Unit at Institut Curie and holds the chair of Epigenetics and Cellular Memory at the Collège de France. "Edith is an outstanding molecular biologist and scientific leader with a lot of international experience. Her clear scientific vision, her participatory leadership style, and her engagement at all levels of research, service and training make her a perfect choice,” said Patrick Cramer, Chair of EMBL Council.
Heidelberg, 15 May 2017 Cell changes drive breast cancer relapse Relapse is now the main cause of death for breast cancer patients. Researchers in the Jechlinger group at EMBL have found that, in mice, the tumour cells that survive therapy and eventually cause a relapse have specific traits that distinguish them from healthy cells. In a study published today in the Journal of Clinical Investigation, the scientists revealed that two of these traits could be promising targets for treatments to reduce tumour recurrence in breast cancer patients.
Heidelberg, 8 May 2017 EMBL spin-off company Luxendo acquired by Bruker In a deal signed today, EMBL spin-off company Luxendo was acquired by the Bruker Corporation. Based in Heidelberg, Germany, Luxendo develops and commercialises microscopes that use the Single Plane Illumination Microscopy (SPIM) technique developed by EMBL researchers.
Monterotondo, 25 April 2017 Developing embryos found to use ancient viral DNA DNA from viruses that once infected our ancestors millions of years ago have remained in our genome to this day. In a study published today in eLife, the Hackett lab at EMBL found that activation of one class of these ancient viral sequences is critical for early mouse embryo development, and identified the protein involved in regulating them.
Barcelona, 10 April 2017 EMBL to open new site in Barcelona At a ceremony in Barcelona today, EMBL and the Spanish government signed an agreement for a new EMBL site to be hosted in the city. EMBL Barcelona will be located on the campus of the Barcelona Biomedical Research Park (PRBB), and researchers at the site will explore how tissues and organs function and develop, and how preventing failures in those processes may help to tackle disease. Alongside cutting-edge research, the site will house state-of-the-art imaging facilities, making pioneering technologies available to scientists worldwide.
Heidelberg, London, 16 February 2017 GSK and EMBL form a new strategic collaboration to enhance understanding of disease and drug mechanisms EMBL and GSK have signed a collaboration agreement to leverage the skills of both organisations to enhance understanding of disease and drug mechanisms and advance early drug discovery. EMBL and GSK will jointly develop and apply cutting edge technologies that will allow the comprehensive characterisation of how a potential new medicine will interact with human biology on a molecular, cellular and organ level to better predict its actions in the human body.
Monterotondo, 9 January 2017 Neural connection keeps instincts in check From fighting the urge to hit someone to resisting the temptation to run off stage instead of giving that public speech, we are often confronted with situations where we have to curb our instincts. Scientists at EMBL have traced exactly which neuronal projections prevent social animals like us from acting out such impulses. The study, published online today in Nature Neuroscience, could have implications for schizophrenia and mood disorders like depression.
- Corriere della Sera , 10 January 2017 Meccanismo in cervello soffoca istinti
- La Repubblica , 10 January 2017 Dalla paura al sesso, ecco come il cervello soffoca gli istinti
Grenoble, 21 December 2016 How flu steals your RNA New work by the Cusack group at EMBL published this week in Nature explains how the influenza virus’ transcription machine interacts with its counterpart in the host cell, offering new possibilities for anti-viral drug design. “We’ve uncovered the details of a mechanism that’s common to all influenza strains, so we believe this could be a good target for developing new flu drugs,” says Stephen Cusack.
Policy regarding use
Press and Picture Releases
EMBL press and picture releases including photographs, graphics, movies and videos are copyrighted by EMBL. They may be freely reprinted and distributed for non-commercial use via print, broadcast and electronic media, provided that proper attribution to authors, photographers and designers is made.